168 related articles for article (PubMed ID: 24175816)
1. Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients.
Fei ZH; Yao CY; Yang XL; Huang XE; Ma SL
Asian Pac J Cancer Prev; 2013; 14(9):5293-9. PubMed ID: 24175816
[TBL] [Abstract][Full Text] [Related]
2. The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients.
Choi YJ; Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Med Oncol; 2012 Jun; 29(2):582-8. PubMed ID: 21327739
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
6. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
7. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
8. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
9. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
10. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
[TBL] [Abstract][Full Text] [Related]
11. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
12. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
[TBL] [Abstract][Full Text] [Related]
14. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer.
Hu LA; Fu Y; Zhang DN; Zhang J
Asian Pac J Cancer Prev; 2013; 14(4):2563-6. PubMed ID: 23725175
[TBL] [Abstract][Full Text] [Related]
15. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.
Oven Ustaalioglu B; Bilici A; Ercan S; Orcun A; Seker M; Ozkan A; Ustaalioglu R; Gumus M
Clin Transl Oncol; 2012 May; 14(5):356-61. PubMed ID: 22551541
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
17. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
[TBL] [Abstract][Full Text] [Related]
18. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic antigen as prognostic factor for metastatic non-small cell lung cancer by percutaneous cryosurgery.
Li H; Tang K; Niu L; Liang Y; Li J; Chen J; Xu K
Cancer Biomark; 2013; 13(5):337-43. PubMed ID: 24440973
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]